Raltitrexed
- Generic Name
- Raltitrexed
- Brand Names
- Tomudex
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22N4O6S
- CAS Number
- 112887-68-0
- Unique Ingredient Identifier
- FCB9EGG971
- Background
Raltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
- Indication
For the treatment of malignant neoplasm of colon and rectum
- Associated Conditions
- Advanced Colorectal Cancer, Pleural Mesotheliomas
CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
- Conditions
- Colon CancerRectal Cancer
- Interventions
- Drug: Ultrafractionated RT and CGA Guided systemic treatment.Other: data prospectively collectedRadiation: Ultrafractionated Radiotherapy
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 124
- Registration Number
- NCT06652412
Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
- Conditions
- FruquintinibRaltitrexedS-1
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Meng Qiu
- Target Recruit Count
- 66
- Registration Number
- NCT06427005
- Locations
- 🇨🇳
Sichuan University West China Hospital, Chengdu, Sichuan, China
🇨🇳West China Hospital, Sichuan University, Chengdu, Sichuan, China
Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- Conditions
- Hepatocellular Carcinoma Resectable
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05766605
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- Conditions
- Liver, Cancer of, Primary Resectable
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT05701436
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
- Conditions
- Recurrent Rectal Cancer
- Interventions
- Drug: PD-1 antibodyDrug: 5FURadiation: Radiation
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 93
- Registration Number
- NCT05628038
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 39
- Registration Number
- NCT05435313
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients
- Conditions
- RegorafenibRaltitrexedColorectal NeoplasmsThird-line Treatment
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 50
- Registration Number
- NCT05426811
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
- Conditions
- Advanced Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 90
- Registration Number
- NCT05160896
- Locations
- 🇨🇳
the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 50
- Registration Number
- NCT05148143
- Locations
- 🇨🇳
the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
Raltitrexed in HIPEC
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 15
- Registration Number
- NCT04761185
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.